ARA290

Cat. No.: HY-P0168
CAS No.: 1208243-50-8
Molecular Formula: C₅₁H₈₄N₁₆O₂₁
Molecular Weight: 1257.31
Sequence Shortening: {Glp}-EQLERALNSS
Target: Others
Pathway: Others
Storage: Powder
-80°C 2 years
-20°C 1 year
In solvent
-80°C 6 months
-20°C 1 month

SOLVENT & SOLUBILITY

In Vitro

DMSO: ≥ 34 mg/mL (27.04 mM)
* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

<table>
<thead>
<tr>
<th>Solvent Concentration</th>
<th>Mass 1 mg</th>
<th>Mass 5 mg</th>
<th>Mass 10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>0.7953 mL</td>
<td>3.9767 mL</td>
<td>7.9535 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.1591 mL</td>
<td>0.7953 mL</td>
<td>1.5907 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.0795 mL</td>
<td>0.3977 mL</td>
<td>0.7953 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description
ARA290 is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment.

In Vitro
ARA290 enhances the proliferation, migration, and resistance to H₂O₂-induced apoptosis of endothelial colony-forming cells (ECFCs)[1]. ARA290 is an EPO-analog peptide without hematopoietic side-effects but may have neurotrophic and antidepressant effects[2].

In Vivo
After ECFC transplantation to mice with CLI, a single ARA290 injection enhances the ischemic/non-ischemic ratio of hindlimb blood flow and capillary density after 28 days and the homing of radiolabeled transplanted cells to the ischemic leg 4 h after transplantation[1]. ARA290 (30 μg/kg, s.c.) prevents progressive worsening of glucose control without affecting body weight of rats. ARA290 significantly decreases glucose AUCs in IPGTT in GK rats[2]. Low-dosage ARA290 (35 μg/kg, i.p.) treatment only slightly attenuates the EAE severity in rats. ARA290-treating group (70
μg/kg, i.p.) significantly delays the onset, decreases the neurologic severity and shortens the duration of EAE in a dose-dependent way[3].

**PROTOCOL**

**Animal Administration**[2]

Diabetic Goto-Kakizaki (GK) rats, originating from Wistar rats, are bred in our department. Normal Wistar (W) rats are used as nondiabetic controls. All animals are about six weeks old and with body weights 100 to 150 g when treatment is initiated. They are kept at 22°C on a reversed 12-h light-dark cycle with free access to food, except when fasted overnight as noted below. Rats are treated over 4 wks with ARA290 by a once daily subcutaneous (s.c.) injection at a dose of 30 μg/kg body weight or PBS. Blood samples for determination of glucose are taken after a small tail incision and analyzed every week before morning s.c. injection of either ARA290 or placebo. During the experimental period, body weights are measured weekly.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**CUSTOMER VALIDATION**


See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

**REFERENCES**


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA